In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS.
Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity...
Objective: To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs.
In relapsing remitting multiple sclerosis (RRMS) patients treated with Lemtrada (alemtuzumab), from Bayer Healthcare and Genzyme/Sanofi, in the Phase III...
EMA�s safety committee (PRAC) has recommended restrictions on the use of Lemtrada (alemtuzumab), from Sanofi, in patients with relapsing remitting...
In this review, we attempt to summarize all the available literature concerning opportunistic infections occurring in patients with MS receiving alemtuzumab.
EMA's safety committee (PRAC) has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated...
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients...
Genzyme announced that the National Institute for Health and Care Excellence (NICE) issued final guidance recommending that Lemtrada (alemtuzumab) from...